Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 11, 2009Clinical & Experimental ImmunologyOpen Access

The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease

View Full Paper
Ask AI
Bookmark
Share

Authors

SISatoko InoueKobe City Medical Center General HospitalHNHiroshi NakaseSapporo Medical UniversityMMMinoru MatsuuraKyorin University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Inoue et al. (2009) studied this question.

synapsesocial.com/papers/6a907939f5c79ce9992db7echttps://doi.org/10.1111/j.1365-2249.2008.03872.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SHORT COMMUNICATION: Comparison of 5-bromo-2-deoxyuridine and [3H]thymidine for studies of hepatocellular proliferation in rodents1989 · 61 citations
  2. 2Natalizumab for Active Crohn's Disease2003 · 815 citations
  3. 3Activation of nuclear factor κB in inflammatory bowel disease1998 · 750 citations
  4. 4Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis2006 · 157 citations
  5. 5Phosphorylation Meets Ubiquitination: The Control of NF-κB Activity2000 · 4,784 citations